Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Gains from Sales and Divestitures (2020 - 2025)

Moleculin Biotech (MBRX) has 5 years of Gains from Sales and Divestitures data on record, last reported at $27348.0 in Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures rose 129.8% year-over-year to $27348.0; the TTM value through Dec 2024 reached $27348.0, up 129.8%, while the annual FY2024 figure was $27348.0, 129.8% up from the prior year.
  • Gains from Sales and Divestitures reached $27348.0 in Q4 2024 per MBRX's latest filing, up from $11901.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $79227.0 in Q3 2020 and bottomed at $11901.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 5 years is $37504.2, with a median of $27635.5 recorded in 2021.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 134.29% in 2022, then tumbled 81.81% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $13205.0 in 2020, then surged by 111.46% to $27923.0 in 2021, then skyrocketed by 134.29% to $65421.0 in 2022, then crashed by 81.81% to $11901.0 in 2023, then soared by 129.8% to $27348.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $27348.0 in Q4 2024, $11901.0 in Q4 2023, and $65421.0 in Q4 2022.